ReGenerCell: Phase IV data

An open-label, European Phase IV trial in 52 patients with chronic venous leg ulcers showed that ReGenerCell plus standard of

Read the full 203 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE